Crohn Hastalığı için geliştirilen ilacın çalışmaları hızlandırılmış prosedüre alındı (İng)
Soligenix gains fast-track status for Crohn’s disease drug
Soligenix’s SGX203, an experimental drug for Crohn’s disease in children, secured fast-track designation from the FDA. The drug contains beclomethasone 17,21-dipropionate, an active corticosteroid, that targets local inflamed tissue. The FDA previously granted the drug orphan-drug status for the same indication.